Tag: AML

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

High-throughput RNA interference (RNAi) screening using a pool of lentiviral shRNAs can be a tool to detect therapeutically relevant synthetic lethal targets in malignancies. We provide a pooled shRNA screening approach to investigate the epigenetic effectors in acute myeloid leukemia (AML). The overall goal of the following video is to…

Continue Reading Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

How a genetic mutation affects the body’s immune system response to viruses, development of blood cancers

Graphical abstract. Credit: Cell Reports (2022). DOI: 10.1016/j.celrep.2022.110856 The body’s innate immune system, active from birth, is the first line of defense against viruses and other pathogens that cause disease. Using vaccination as an example, after receiving a vaccine, pain, redness, or swelling may occur at the injection site. This…

Continue Reading How a genetic mutation affects the body’s immune system response to viruses, development of blood cancers

Researchers Develop Allogeneic CART for Relapsed or Refractory T-ALL Using Base Editing

A group of researchers at Children’s Hospital of Philadelphia (CHOP), in collaboration with Beam Therapeutics, have tested and developed an “off-the-shelf” chimeric antigen receptor T-cell (CART) using base editing, which is designed to allow for precise editing of the CART with less risk of unwanted and unforeseen outcomes that may…

Continue Reading Researchers Develop Allogeneic CART for Relapsed or Refractory T-ALL Using Base Editing

CENTURY THERAPEUTICS, INC. Management’s discussion and analysis of financial condition and results of operations (form 10-Q)

The following discussion and analysis should be read in conjunction with our financial statements and accompanying notes included in this Quarterly Report on Form 10-Q and the financial statements and accompanying notes thereto for the fiscal year ended December 31, 2021 and the related Management’s Discussion and Analysis of Financial…

Continue Reading CENTURY THERAPEUTICS, INC. Management’s discussion and analysis of financial condition and results of operations (form 10-Q)

CALITHERA BIOSCIENCES, INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and related notes included in Part I, Item 1 of this report. This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of…

Continue Reading CALITHERA BIOSCIENCES, INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)

r – How to keep row names when running h2o automl?

I’m performing a classification task and in particular my goal is to detect the churn of the customers of a company. I’m currently using the library lares that takes advantage of the h2o.automl() function from h2o library: aml = h2o_automl(df, y = target,max_models = 100) #run the models aml$scores_test %>%…

Continue Reading r – How to keep row names when running h2o automl?

aCGH – Allie: Result by abbreviation

1  array comparative genomic hybridization(1473 times) Neoplasms(306 times) FISH (238 times)CNVs (135 times)MLPA (72 times) 2003 1-Mb resolution array-based comparative genomic hybridization using a BAC clone set optimized for cancer gene analysis. 2  array CGH(43 times) Neoplasms(12 times) CNVs (7 times)FISH (3 times)ID (3 times) 2003 Combined array comparative genomic hybridization and…

Continue Reading aCGH – Allie: Result by abbreviation

Biomea Fusion Reports Preclinical Data on BMF-219 and Trial

Covalent menin inhibitor BMF-219 showed strong cytotoxic activity as a single agent at similar concentrations across multiple preclinical patient derived (PDX) models ex vivo, including diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and pancreatic cancer Single agent BMF-219 demonstrated pronounced anti-cancer activity…

Continue Reading Biomea Fusion Reports Preclinical Data on BMF-219 and Trial

Expression profiling of N 6-methyladenosine modified circRNAs in acute myeloid leukemia

Biochem Biophys Res Commun . 2022 Feb 23;601:137-145. doi: 10.1016/j.bbrc.2022.02.087. Online ahead of print. Affiliations Expand Affiliations 1 Fujian Institute of Hematology, Fujian Medical Center of Hematology, Clinical Research Center for Hematological Malignancies of Fujian Province, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, 350001,…

Continue Reading Expression profiling of N 6-methyladenosine modified circRNAs in acute myeloid leukemia

Research Roundup: New Insights into Alzheimer’s, ALS and FTD

BSIP/UIG Via Getty Images One particular gene variant, APOE4, is associated with an increased risk of Alzheimer’s disease. But why that is the case, what the mechanism of action is, has eluded researchers. At least one pathway has been determined, and it has possible repercussions in developing therapies against the…

Continue Reading Research Roundup: New Insights into Alzheimer’s, ALS and FTD

How to Remove All Session Objects after H2O AutoML?

The recommended way to clean only your work is to use h2o.remove(aml). This will delete the automl instance on the backend and cascade to all the submodels and attached objects like metrics. It won’t delete the frames that you provided though (e.g. training_frame). You can use h2o.ls() to list the…

Continue Reading How to Remove All Session Objects after H2O AutoML?

Gilead’s CD47 clinical hold expands as CEO O’Day expresses ‘sense of urgency’ in getting trials back on track

Gilead revealed that a partial clinical hold for its CD47 targeted cancer hopeful is larger than originally thought. Last week, the California-based biotech shared that a handful of trials for magrolimab in combination with azacytidine had been placed on a partial clinical hold because of an “apparent imbalance” in adverse reactions…

Continue Reading Gilead’s CD47 clinical hold expands as CEO O’Day expresses ‘sense of urgency’ in getting trials back on track

NuProbe Technology Showcases Quantitative PCR for

Houston, January 18, 2022 (GLOBE NEWSWIRE) – NuProbe, a genomics and molecular diagnostics company that develops ultra-sensitive tests for precision cancer research, today released research demonstrating new technology to qualitatively and quantitatively detect multiple low-grade variants frequency in a quantitative PCR (qPCR reaction). The new allele-specific BDA technology (As-BDA) uses…

Continue Reading NuProbe Technology Showcases Quantitative PCR for

Failure to detect mutations in U2AF1 due to changes in the GRCh38 reference sequence

Materials and Methods Genomic data was collected as part of the MDS National History Study or The Cancer Genome Atlas project and consented appropriately under those protocols 8 Sekeres M.A. Gore S.D. Stablein D.M. DiFronzo N. Abel G.A. DeZern A.E. Troy J.D. Rollison D.E. Thomas J.W. Waclawiw M.A. Liu J.J….

Continue Reading Failure to detect mutations in U2AF1 due to changes in the GRCh38 reference sequence

h2o.explain function – RDocumentation

Description The H2O Explainability Interface is a convenient wrapper to a number of explainabilty methods and visualizations in H2O. The function can be applied to a single model or group of models and returns a list of explanations, which are individual units of explanation such as a partial dependence plot…

Continue Reading h2o.explain function – RDocumentation

Celyad Oncology Presents Updates on shRNA-Based CAR T

Data continues to support the versatile potential of non-gene edited shRNA technology with updates from the CYAD-02 and CYAD-211 clinical programs Management to host conference call today December 13th at 2:30 p.m. CET / 8:30 a.m. EST MONT-SAINT-GUIBERT, Belgium, Dec. 13, 2021 (GLOBE NEWSWIRE) — Celyad Oncology SA (Euronext &…

Continue Reading Celyad Oncology Presents Updates on shRNA-Based CAR T

PyTorch model conversion – Technical Support

I’m unable to convert a model in pytorch This is the script to download the pretrained weights import torch import torchvision.models as models resnet18 = models.resnet18(pretrained=True) torch.save(resnet18, ‘resnet18.pt’) This is the script for converting ./convert –model-name resnet18 –platform pytorch –model resnet18.pt –input-size-list ‘3,224,224’ –mean-values ‘103.94,116.78,123.68,58.82’ –quantized-dtype asymmetric_affine –kboard VIM3 –print-level…

Continue Reading PyTorch model conversion – Technical Support

Reliability of Cell-Free DNA (cfDNA) Next Generation Sequencing in Predicting Chromosomal Structural Abnormalities and Cytogenetic-Risk Stratification of Patients with Myeloid Neoplasms

Oral and Poster Abstracts 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III Translational Research Maher Albitar, MD1*, Andrew Ip, MD, MSc2, Andre H. Goy, MD3*, Jeffrey Justin Estella, BS, MS1*, Ivan De Dios, BS1*,…

Continue Reading Reliability of Cell-Free DNA (cfDNA) Next Generation Sequencing in Predicting Chromosomal Structural Abnormalities and Cytogenetic-Risk Stratification of Patients with Myeloid Neoplasms

Non-genetic determinants of malignant clonal fitness at single-cell resolution

1. Turajlic, S., Sottoriva, A., Graham, T. & Swanton, C. Resolving genetic heterogeneity in cancer. Nat. Rev. Genet. 20, 404–416 (2019). CAS  PubMed  Google Scholar  2. Marine, J. C., Dawson, S. J. & Dawson, M. A. Non-genetic mechanisms of therapeutic resistance in cancer. Nat. Rev. Cancer 20, 743–756 (2020). CAS …

Continue Reading Non-genetic determinants of malignant clonal fitness at single-cell resolution

MD Anderson research highlights 9 December

ATLANTA ― The University of Texas MD Anderson Cancer Center‘s Research Highlights provides a glimpse into basic, translational and clinical cancer research from MD Anderson experts. This special edition features presentations at the 2021 American Society of Hematology (ASH) Annual Meeting on innovative targeted therapies, new combination approaches, and novel…

Continue Reading MD Anderson research highlights 9 December

GRRDUser Manual [PDF] | Documents Community Sharing

* The preview only display some random pages of manuals. You can download full content via the form below. Microsoft Word Add-In for the GenePattern Reproducible Research Document July 2009 Introduction…………………………………………………………………………………………………………………. 3 About GenePattern…………………………………………………………………………………………………… 3 How GenePattern and the GRRD Add-In Work Together…………………………………………………4 Reproducibility of Document Interactions………………………………………………………………………4 Installing and Uninstalling…

Continue Reading GRRDUser Manual [PDF] | Documents Community Sharing

FDA clears IND application for CRISPR-edited T-cell receptor therapy to treat AML

September 17, 2021 1 min read ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process…

Continue Reading FDA clears IND application for CRISPR-edited T-cell receptor therapy to treat AML

Intellia Therapeutics Set to Enter Clinic with First Solo Ex Vivo Candidate

Courtesy Intellia Therapeutics Intellia Therapeutics is celebrating another first today as the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for NTLA-5001, its first wholly-owned ex vivo CRISPR genome editing candidate. NTLA-5001 is being developed for the treatment of acute myeloid leukemia (AML). Intellia…

Continue Reading Intellia Therapeutics Set to Enter Clinic with First Solo Ex Vivo Candidate

Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia | DNA RNA and Cells

Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia Details Category: DNA RNA and Cells Published on Thursday, 16 September 2021 17:52 Hits: 130 NTLA-5001 is Intellia’s first ex vivo candidate using its proprietary cell engineering…

Continue Reading Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia | DNA RNA and Cells

Paired-end reads reported without mates: how to play matchmaker?

Hi Everyone, I am currently looking at Acute Myeloid Leukemia (AML) paired-end WGS samples from the TARGET data ocg.cancer.gov/programs/target/target-methods#3241. A bioinformatician in our group remapped the samples from hg19 to hg38. Unfortunately, we do not have any copies of the hg19 version anymore. However, when I try to run anything…

Continue Reading Paired-end reads reported without mates: how to play matchmaker?

Oncogene Concatenated Enriched Amplicon Nanopore Sequencing for rapid, accurate, and affordable somatic mutation detection | Genome Biology

Stochastic Amplicon Ligation. DNA samples for oncology sequencing are typically extracted from FFPE tissues and can have average lengths of less than 500 nt due to accumulated chemical damage [18]. We developed the Stochastic Amplicon Ligation (SAL) method to enzymatically concatenate many short DNA molecules together to utilize the long-read…

Continue Reading Oncogene Concatenated Enriched Amplicon Nanopore Sequencing for rapid, accurate, and affordable somatic mutation detection | Genome Biology

Cellectis Announces Participation in Five Investor

NEW YORK, Aug. 26, 2021 (News) — Cellectis S.A. (NASDAQ: CLLS – EURONEXT Progress: ALCLS) (the “Company”), a gene-modifying platform firm with scientific-stage immuno-oncology plans making use of allogeneic chimeric antigen receptor (Vehicle)-T cells and gene remedy courses for monogenic diseases, now declared that management plans to take part in…

Continue Reading Cellectis Announces Participation in Five Investor

How get Genetic Positions of SNPs?

How get Genetic Positions of SNPs? 0 I have some datasets related to different diseases like AML, etc. The data which I have include markers’ genotypes (AA, AB, BB) and some other information like chromosome number, physical position, strand,etc. For some reasons I need to have the genetic positions of…

Continue Reading How get Genetic Positions of SNPs?

Integrated bioinformatics analysis to identify abnormal CC

Introduction In recent years, the morbidity and mortality of colon cancer have increased rapidly, both being ranked fourth worldwide. Although surgery-based comprehensive treatments improve the prognosis of colon cancer, because of the lack of available means for early diagnosis, the mortality level remains high for patients with advanced-stage cancer. The…

Continue Reading Integrated bioinformatics analysis to identify abnormal CC

Bioconductor – SingscoreAMLMutations

DOI: 10.18129/B9.bioc.SingscoreAMLMutations     Using singscore to predict mutations in AML from transcriptomic signatures Bioconductor version: Release (3.13) This workflow package shows how transcriptomic signatures can be used to infer phenotypes. The workflow begins by showing how the TCGA AML transcriptomic data can be downloaded and processed using the TCGAbiolinks…

Continue Reading Bioconductor – SingscoreAMLMutations

ICA – Reconstruction Errors

ICA – Reconstruction Errors 0 Hello people! I am completely new to the topic of ML and Omics and at all in the bioinformatics field. To gather some knowledge I started to work through a book I found on the internet and there is the following task: “Produce a 10-component…

Continue Reading ICA – Reconstruction Errors